Credit Suisse: Copaxone sales to plunge 90%

Credit Suisse sees Copaxone sales falling from $4 billion annually to $400,000 in 2019 and predicts annual sales of over $1 billion for Laquinimod.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) branded drug Copaxone will be the main loser in the multiple sclerosis treatment shift which is currently underway, according to a report by Credit Suisse entitled "Multiple Sclerosis It's a Revolution."

The report says that Tecfidera, the oral multiple sclerosis treatment launched several months ago by Biogen will be the main winner.

Credit Suisse sees annual sales of Copaxone falling 90% from about $4 billion in 2012 to less than $400,000 in 2019. The main reasons for this are well known and have long been acknowledged by investors- competition from rival branded drugs that are new on the market such as Tecfidera, for which it sees sales of $5.2 billion annually by 2019, and Novartis's Gilenya, for which it predicts sales of $3.2 billion annually by 2019. Copaxone will also face competition from generic entries after its patent expires.

Credit Suisse does expect Laquinimod, Teva's oral treatment for multiple sclerosis, to come onto the market by 2014, and to start being sold in the US as well in 2017, but sees annual worldwide sales of only $428 million in the US and $649 million in the rest of the world by 2019.

Published by Globes [online], Israel business news - - on October 2, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017